119
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study

ORCID Icon, ORCID Icon, , , , ORCID Icon, , , , , , , , ORCID Icon & ORCID Icon show all
Pages 517-533 | Published online: 08 Mar 2022

References

  • Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. PubMed PMID: 28182564. doi:10.1183/13993003.00214-2017
  • O’Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105(7):1030–1036. PubMed PMID: 21498063. doi:10.1016/j.rmed.2011.03.014
  • Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med. 2014;24(1):14003. PubMed PMID: 24841833; PMCID: PMC4373257. doi:10.1038/npjpcrm.2014.3
  • Beeh KM, Watz H, Puente-Maestu L, et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial. BMC Pulm Med. 2014;14(1):209. PubMed PMID: 25539654; PMCID: PMC4364572. doi:10.1186/1471-2466-14-209
  • Ni H, Moe S, Soe Z, Myint KT, Viswanathan KN. Combined Aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev PubMed PMID: 30536566; PMCID: PMC6517126. 2018;12:CD011594. doi:10.1002/14651858.CD011594.pub2
  • Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest. 2005;128(3):1168–1178. PubMed PMID: 16162703. doi:10.1378/chest.128.3.1168
  • Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis PubMed PMID: 22973092; PMCID: PMC3430121. 2012;7:503–513. doi:10.2147/COPD.S32451
  • Di Marco F, Sotgiu G, Santus P, et al. Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respir Res. 2018;19(1):18. PubMed PMID: 29368604; PMCID: PMC5784692. doi:10.1186/s12931-018-0721-3
  • Watz H, Troosters T, Beeh KM, et al. ACTIVATE: the effect of Aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis PubMed PMID: 28883722; PMCID: PMC5574699. 2017;12:2545–2558. doi:10.2147/COPD.S143488
  • Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. PubMed PMID: 27181606. doi:10.1056/NEJMoa1516385
  • Watz H, Krippner F, Kirsten A, Magnussen H, Vogelmeier C. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease–a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med. 2014;14(1):158. PubMed PMID: 25280934; PMCID: PMC4197315. doi:10.1186/1471-2466-14-158
  • Watz H, Mailander C, Baier M, Kirsten A. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study). BMC Pulm Med. 2016;16(1):95. PubMed PMID: 27301417; PMCID: PMC4908762. doi:10.1186/s12890-016-0256-7
  • O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840. PubMed PMID: 15218994. doi:10.1183/09031936.04.00116004
  • Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021–1032. PubMed PMID: 29664681. doi:10.1164/rccm.201706-1288OC
  • Augustin IML, Wouters EFM, Houben-Wilke S, et al. Comprehensive lung function assessment does not allow to infer response to pulmonary rehabilitation in patients with COPD. J Clin Med. 2018;8(1):27. PubMed PMID: 30591662. doi:10.3390/jcm8010027
  • Augustin IML, Spruit MA, Houben-Wilke S, et al. The respiratory physiome: clustering based on a comprehensive lung function assessment in patients with COPD. PLoS One. 2018;13(9):e0201593. PubMed PMID: 30208035; PMCID: PMC6135389 (SCO115406). doi:10.1371/journal.pone.0201593
  • Spruit MA, Augustin IM, Vanfleteren LE, et al. Differential response to pulmonary rehabilitation in COPD: multidimensional profiling. Eur Respir J. 2015;46(6):1625–1635. PubMed PMID: 26453626. doi:10.1183/13993003.00350-2015
  • Naya IP, Tombs L, Muellerova H, Compton C, Jones PW. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir Res. 2018;19(1):222. PubMed PMID: 30453972; PMCID: PMC6245880. doi:10.1186/s12931-018-0928-3
  • Kostikas K, Greulich T, Mackay AJ, et al. Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study. ERJ Open Res. 2019;5(1):00243–2018. PubMed PMID: 30815470; PMCID: PMC6387992. doi:10.1183/23120541.00243-2018
  • Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–64. PubMed PMID: 24127811. doi:10.1164/rccm.201309-1634ST
  • Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–522. PubMed PMID: 16135736. doi:10.1183/09031936.05.00035005
  • Coates AL, Peslin R, Rodenstein D, Stocks J. Measurement of lung volumes by plethysmography. Eur Respir J. 1997;10(6):1415–1427. PubMed PMID: 9192953. doi:10.1183/09031936.97.10061415
  • Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. PubMed PMID: 16055882. doi:10.1183/09031936.05.00034805
  • Gimeno-Santos E, Raste Y, Demeyer H, et al. The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease. Eur Respir J. 2015;46(4):988–1000. PubMed PMID: 26022965; PMCID: PMC4589432. doi:10.1183/09031936.00183014
  • Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33(2):262–272. PubMed PMID: 19010994. doi:10.1183/09031936.00024608
  • Kohonen T. 3.1 A Qualitative Introduction to the SOM and 3.2 The Original Incremental SOM Algorithm. In: Self-Organizing Maps. Springer; 2001: 106–115.
  • Oja E, Kaski S, Eds. Kohonen Maps. Elsevier Science B.V.; 1999.
  • Bhatt SP, Soler X, Wang X, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(2):178–184. PubMed PMID: 26808615; PMCID: PMC5003216. doi:10.1164/rccm.201511-2219OC
  • Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011;105(4):580–587. PubMed PMID: 21183326. doi:10.1016/j.rmed.2010.11.019
  • Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily Aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011;12(1):55. PubMed PMID: 21518460; PMCID: PMC3098801. doi:10.1186/1465-9921-12-55
  • Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax. 2003;58(8):654–658. PubMed PMID: 12885977; PMCID: PMC1746769. doi:10.1136/thorax.58.8.654
  • Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12(1):161. PubMed PMID: 22206353; PMCID: PMC3287973. doi:10.1186/1465-9921-12-161
  • Bhatt SP, Wells JM, Kim V, et al. Radiological correlates and clinical implications of the paradoxical lung function response to beta(2) agonists: an observational study. Lancet Respir Med. 2014;2(11):911–918. PubMed PMID: 25217076; PMCID: PMC4306040. doi:10.1016/S2213-2600(14)70185-7
  • Rossi A, Aisanov Z, Avdeev S, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109(7):785–802. PubMed PMID: 25892293. doi:10.1016/j.rmed.2015.03.010
  • O’Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with “irreversible” emphysema. Eur Respir J. 2001;18(6):914–920. PubMed PMID: 11829096. doi:10.1183/09031936.01.00216501
  • Schermer T, Heijdra Y, Zadel S, et al. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med. 2007;101(6):1355–1362. PubMed PMID: 17098407. doi:10.1016/j.rmed.2006.09.024
  • Kosteli MC, Heneghan NR, Roskell C, et al. Barriers and enablers of physical activity engagement for patients with COPD in primary care. Int J Chron Obstruct Pulmon Dis. 2017;12:1019–1031. PubMed PMID: 28405162; PMCID: PMC5378459. doi:10.2147/COPD.S119806
  • Wilson T, Holt T, Greenhalgh T. Complexity science: complexity and clinical care. BMJ. 2001;323(7314):685–688. PubMed PMID: 11566836; PMCID: PMC1121241. doi:10.1136/bmj.323.7314.685
  • Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(10):1333–1343. PubMed PMID: 27409253. doi:10.1164/rccm.201604-0733OC